Blog

Accelerate in vivo CAR-T development with custom IVT mRNA, targeted LNP formulation, antibody conjugation, stability optimization, and scalable CRO solutions.

Learn how 5′ UTR engineering can optimize mRNA translation in T cells, reduce tonic signaling, and improve CAR-T cell therapy performance.

Learn about LNP formulation and mRNA encapsulation, including lipid selection, payload scale, QC, particle size, encapsulation efficiency, and service options.

Explore custom IVT mRNA synthesis, including workflow, service grades, purification, capping, modified nucleotides, Poly(A) tails, QC and project timelines.

Messenger RNA (mRNA) holds great potential for vaccines, protein replacement therapy, cancer immunotherapy, in vivo cell therapy and gene editing. However, naked mRNA faces critical barriers for in vivo administration: it is rapidly degraded by ubiquitous ribonucleases in bodily fluids, triggers strong innate immune responses, and cannot spontaneously cross negatively charged cell membranes.

​In vitro transcription (IVT) has become the foundational manufacturing technology for modern mRNA-based modalities, including prophylactic vaccines, cancer immunotherapies, protein replacement agents, in vivo cell therapies and gene editing systems. Despite widespread adoption, lab-scale mRNA synthesis continues to face persistent technical challenges: